Recent developments in the treatment of chronic lymphocytic leukemia (CLL) have included a fixed-duration oral combination ...

Pirtobrutinib is currently approved for the treatment of patients with CLL/SLL who have received at least 2 prior lines of therapy.

Acalabrutinib plus obinutuzumab shows superior long-term outcomes in treatment-naive chronic lymphocytic leukemia.

Please provide your email address to receive an email when new articles are posted on . In this video, Joshua Brody, MD, discusses results from an ongoing phase 1a study of bexobrutideg, a novel ...

CLL-related immune dysfunction, along with therapy-associated immunosuppression, contributes to impaired tumor surveillance.

Junk DNA” may hold the key to treating tough cancers. Existing drugs exploit weaknesses in cells with gene mutations. Researchers at King’s College London have identified a promising strategy for ...

AstraZeneca has agreed to lower prescription drug costs for Medicaid under a deal with the Trump administration.

Leukemia is a blood cancer that disrupts normal cell production, leading to infection risk, anemia and bleeding, and requiring tailored treatments. Leukemia is a type of cancer that begins in the ...

A new tool developed by Weill Cornell Medicine and the University of Adelaide investigators has enhanced the ability to track multiple gene mutations while simultaneously recording gene activity in ...

The Chronic Lymphocytic Leukemia Market is set for significant expansion over the next decade. Valued at USD 5.4 billion in 2025, the market is projected to grow to USD 10.3 billion by 2035, ...